As of May 22, 2025, Sigilon Therapeutics, Inc. (SGTX) carries a Weighted Average Cost of Capital (WACC) of 7.2%. WACC reflects the blended rate Sigilon Therapeutics, Inc. must pay to both equity and debt holders.
Within that, the cost of equity is 6.4%, the cost of debt is 7.0%, and the effective tax rate is 26.2%.
Breakdown of WACC Components
What It Means for Investors
With a selected WACC of 7.2%, Sigilon Therapeutics, Inc. must ensure any new investment returns exceed this threshold to generate shareholder value. This level reflects an attractive low cost of capital.